Related Experiment Video
Updated: May 20, 2025
Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
Chronic thromboembolic pulmonary hypertension.
John-Peder Escobar Kvitting1, Håvard Ravnestad2, Rune Andersen3
1Thoraxkirurgisk avdeling, Oslo universitetssykehus, Rikshospitalet, og, Institutt for klinisk medisin, Universitetet i Oslo.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a serious condition often following pulmonary embolism. Pulmonary endarterectomy is the primary treatment, with angioplasty and medical options for inoperable patients.
Area of Science:
- Cardiology
- Pulmonary Medicine
- Vascular Surgery
Background:
- Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe complication of pulmonary embolism.
- CTEPH is associated with significant morbidity and mortality.
- Early diagnosis and management are crucial for improving patient outcomes.
Purpose of the Study:
- To provide a comprehensive clinical overview of CTEPH treatments.
- To discuss current pharmacological, endovascular, and surgical therapeutic options.
- To highlight the importance of tailored treatment strategies for CTEPH patients.
Main Methods:
- Review of current literature on CTEPH management.
- Analysis of treatment outcomes for pulmonary endarterectomy, balloon pulmonary angioplasty, and medical therapies.
- Clinical guideline synthesis for treatment selection.
Main Results:
- Pulmonary endarterectomy is the gold standard, offering potential cure and improving hemodynamics and exercise capacity.
- Percutaneous balloon pulmonary angioplasty serves as a viable alternative for inoperable patients.
- Medical therapy offers symptomatic relief and hemodynamic improvement in select cases.
Conclusions:
- Treatment decisions for CTEPH should be individualized based on patient operability and disease characteristics.
- A multidisciplinary approach is essential for optimal management of CTEPH.
- Ongoing research is vital for advancing CTEPH treatment modalities.
More Related Videos
07:41Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...